Výsledky vyhledávání - "John A. Strader"

Akademický článek

Single-Prolonged Stress Impairs Prefrontal Cortex Control of Amygdala and Striatum in Rats

Autor: Veronica M. Piggott, Kelly E. Bosse, Michael J. Lisieski, John A. Strader, Jeffrey A. Stanley, Alana C. Conti, Farhad Ghoddoussi, Shane A. Perrine

Publikováno v: Frontiers in Behavioral Neuroscience, Vol 13 (2019)

Medial prefrontal cortex (mPFC), amygdala, and striatum neurocircuitry has been shown to play an important role in post-traumatic stress disorder (PTSD) pathology in humans. Clinical studies show hypoactivity in the mPFC and hyperactivity in the amyg

Externí odkaz: https://doaj.org/article/cd20eb63bc364c39997f2c7bedaf84c0

Zobrazit plný text záznamu

Data from Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma

Autor: Robert Z. Orlowski, Jeffrey A. Nemeth, Mohamed H. Zaki, Robert E. Corringham, John S. Strader, Sally A. Hunsucker, George W. Small, Deborah J. Kuhn, Qing Chen, Peter M. Voorhees

Purpose: Inhibition of the proteasome leads to the activation of survival pathways in addition to those that promote cell death. We hypothesized that down-regulation of interleukin-6 (IL-6) signaling using the monoclonal antibody CNTO 328 would enhan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e8da62fc2c8443f5d600227f1aa2f6a
https://doi.org/10.1158/1078-0432.c.6516807.v1

Zobrazit plný text záznamu

Differences in hippocampal serotonergic activity in a mouse single prolonged stress paradigm impact discriminant fear acquisition and retention

Autor: Deane Aikins, Shane A. Perrine, Nina Bihani, Robert J. Kohler, John A. Strader

Publikováno v: Neuroscience letters. 639

A mouse model of traumatic stress provided insight into a mechanism of individual differences in conditioned fear responding. Hippocampal serotonergic activity (metabolic turnover) was associated with increased behavioral freezing during fear acquisi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c32b71fbd6b3b57791d9173abccc08c
https://pubmed.ncbi.nlm.nih.gov/28025114

Zobrazit plný text záznamu

Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma

Autor: Deborah J. Kuhn, Jeffrey A. Nemeth, Peter M. Voorhees, Mohamed H. Zaki, Robert Corringham, Sally A. Hunsucker, George W. Small, John S. Strader, Qing Chen, Robert Z. Orlowski

Publikováno v: Clinical Cancer Research. 13:6469-6478

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97d80fcc7d270795afdc7ae89e3e0f8f
https://doi.org/10.1158/1078-0432.ccr-07-1293

Zobrazit plný text záznamu

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Autor: Mark K. Bennett, Asher A. Chanan-Khan, Kevin D. Shenk, Qing Chen, Fijs W. B. van Leeuwen, Robert Z. Orlowski, Susan Demo, John S. Strader, Congcong M. Sun, Peter M. Voorhees, Deborah J. Kuhn

The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib, a first-in-class, reversible proteasome inhibitor, for relapsed/refractory multiple myeloma (MM). However, many patients have disease that does not

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::851c3aa64e136380bc550ac99d196339
https://europepmc.org/articles/PMC2200918/

Zobrazit plný text záznamu

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study

Autor: Peter M. Voorhees, Robert Z. Orlowski, Diane Winans, Dominic T. Moore, Cristina Gasparetto, Kristy L. Richards, Jennifer MacLean, John S. Strader, Madlyn Ferraro, David D. Hurd, Keren Osman, Reynaldo Garcia

Publikováno v: Blood. 118:3985-3985

Abstract 3985 Introduction: Although the combination of PLD and B improved time to progression (TTP) compared with B alone in patients (pts) with R/R MM, the overall response rate (ORR) of the regimen was only 44%, while TTP was 9.3 months. As such,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ab2e5106556a797b311e9b84445696b2
https://doi.org/10.1182/blood.v118.21.3985.3985

Zobrazit plný text záznamu

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Autor: Cristina Gasparetto, Madlyn Ferraro, Peter M. Voorhees, Kristy L. Richards, Jennifer MacLean, John S. Strader, Dominic T. Moore, Robert Z. Orlowski, Keren Osman, Reynaldo Garcia, David D. Hurd, Diane Winans

Publikováno v: Blood. 116:1955-1955

Abstract 1955 Introduction: The histone deacetylase inhibitor vorinostat has additive to synergistic activity in combination with anthracyclines and proteasome inhibitors in preclinical models of multiple myeloma (MM). We therefore sought to evaluate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6975e59eda93f501b9bc72cc03e3f5db
https://doi.org/10.1182/blood.v116.21.1955.1955

Zobrazit plný text záznamu

Development of Immunoproteasome-Specific Inhibitors as Novel Anti-Cancer Drugs

Autor: Deborah J. Kuhn, Zhigen Hu, Peter M. Voorhees, Frank J. Bruzzese, Robert Z. Orlowski, John S. Strader, Jefrey P Ciavarri, Qing Chen

Publikováno v: Blood. 108:3458-3458

Introduction: The proteasome is a large (~2.5 MDa), ATP-dependent, intracellular protease responsible for degrading ubiquitinated proteins as part of the ubiquitin-proteasome pathway. The immunoproteasome is a unique proteasomal variant with distinct

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::00ab7af6b89f2e73f2b547ffc95e015f
https://doi.org/10.1182/blood.v108.11.3458.3458

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání